RA
RANI.US Rani Therapeutics Holdings Inc
- Market cap
- USD 64.6M
- P/E
- -
- P/B
- 1.88x
- ROE
- -86.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is RANI.US undervalued?
Graham numberThe Graham number of Rani Therapeutics Holdings Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Rani Therapeutics Holdings Inc fundamental analysis
No fundamental analysis for Rani Therapeutics Holdings Inc yet.
Rani Therapeutics Holdings Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Rani Therapeutics Holdings Inc
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its produ…
Full company profileRani Therapeutics Holdings Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Rani Therapeutics Holdings Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 979K | 462K | 2.72M | 0.00 | 0.00 | 1.03M | 1.63M | 6.83M |
| Gross Profit | 979K | 462K | 2.72M | -1.31M | -822K | 1.03M | 733K | 6.62M |
| Operating Income | -27.1M | -16.5M | -51.6M | -63.5M | -66.1M | -53.3M | -38.3M | -35.2M |
| EBITDA | -26.0M | -16.0M | -52.1M | -61.7M | -62.0M | -50.5M | -37.2M | -33.4M |
| Net Income | -26.6M | -16.7M | -8.33M | -30.6M | -34.0M | -30.0M | -29.7M | -29.5M |
| EPS | -1.42 | -0.89 | -0.43 | -1.28 | -1.33 | -1.05 | -0.45 | -0.15 |
| Balance Sheet | ||||||||
| Total Assets | 23.0M | 79.4M | 124M | 108M | 57.9M | 36.6M | 58.6M | 52.5M |
| Total Liabilities | 120M | 193M | 2.64M | 34.0M | 32.5M | 33.1M | 17.1M | 11.2M |
| Shareholders' Equity | -96.6M | -113M | 47.4M | 36.9M | 12.9M | 1.99M | 33.0M | 34.0M |
| Cash & Short-term Investments | 16.5M | 73.1M | 117M | 98.5M | 48.5M | 27.6M | 49.7M | 45.3M |
| Total Debt | 116M | 3.77M | - | 30.2M | 30.1M | 29.7M | 4.32M | 3.15M |
| Cash Flow | ||||||||
| Operating Cash Flow | -26.3M | -15.0M | -32.2M | -46.5M | -51.2M | -35.5M | -18.7M | -31.0M |
| Capital Expenditure | 1.58M | 1.20M | 506K | 1.62M | 1.23M | 268K | 88.0K | 307K |
| Free Cash Flow | -27.8M | -16.2M | -32.8M | -48.1M | -52.5M | -35.8M | -18.8M | -31.4M |
| Ratios | ||||||||
| ROE | - | - | -17.6% | -83.0% | -264.0% | -1,506.9% | -89.9% | -86.9% |
| ROA | -115.5% | -21.0% | -6.7% | -28.3% | -58.7% | -81.9% | -50.6% | -56.2% |
| Net Profit Margin | -2,716.8% | -3,615.4% | -306.6% | - | - | -2,920.0% | -1,817.1% | -432.4% |
| Debt to Equity | - | - | - | 0.82x | 2.34x | 14.91x | 0.13x | 0.09x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Rani Therapeutics Holdings Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 29.6M | 1.24 | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Rani Therapeutics Holdings Inc
- Insiders 4.91%
- Institutions 47.29%
- Public & others 47.80%
- Shares outstanding 115M
- Free float 82.4M
Top funds holding RANI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 3.65M | 3.16% | 0.00% | Sep 2026 |
| Abante Quant Value FI | 624K | 0.54% | 0.00% | Aug 2026 |
| Fidelity Extended Market Index | 451K | 0.39% | +11.85% | Sep 2026 |
| Fidelity Total Market Index | 138K | 0.12% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 115K | 0.10% | 0.00% | Sep 2026 |
| iShares Nasdaq US Biotech ETF USD Acc | 77.2K | 0.07% | +0.21% | Oct 2026 |
| Vanguard Balanced Index Inv | 49.9K | 0.04% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 31.8K | 0.03% | 0.00% | Sep 2026 |
| Luceiro Capital Value Fund FI | 26.3K | 0.02% | 0.00% | Sep 2026 |
| China Universal NASDAQ Bio-Tch ETF(QDII) | 17.9K | 0.02% | +12.54% | Jun 2026 |
| Invesco Nasdaq Biotechnology ETF | 8.56K | 0.01% | 0.00% | Oct 2026 |
| Fidelity Nasdaq Composite Index | 6.77K | 0.01% | -90.51% | Aug 2026 |
| ProShares Ultra Nasdaq Biotechnology | 4.61K | 0.00% | 0.00% | Oct 2026 |
| Knights of Columbus U.S. All Cap Idx I | 559.00 | 0.00% | +16.70% | Sep 2026 |
Top institutions holding RANI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Samsara BioCapital, LLC | 10.4M | 8.98% | +21.99% | Jun 2026 |
| RA Capital Management, LLC | 8.50M | 7.36% | 0.00% | Jun 2026 |
| Awm Investment Company Inc | 7.50M | 6.49% | +15.38% | Jun 2026 |
| Vanguard Capital Management, LLC | 4.56M | 3.95% | -1.29% | Jun 2026 |
| Longaeva Partners L.P. | 2.33M | 2.02% | 0.00% | Jun 2026 |
| Polar Asset Management Partners | 2.32M | 2.01% | 0.00% | Jun 2026 |
| Siren, L.L.C. | 2.00M | 1.73% | 0.00% | Jun 2026 |
| Heights Capital Management Inc | 935K | 0.81% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 891K | 0.77% | -1.40% | Jun 2026 |
| Citadel Advisors Llc | 642K | 0.56% | 0.00% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 586K | 0.51% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 541K | 0.47% | +25.49% | Sep 2026 |
| Nan Fung Group Holdings Ltd | 494K | 0.43% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 486K | 0.42% | +193.42% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 458K | 0.40% | +0.68% | Jun 2026 |
| State Street Corp | 373K | 0.32% | 0.00% | Jun 2026 |
| BlackRock Inc | 342K | 0.30% | -38.57% | Jun 2026 |
| United Services Automobile Association | 303K | 0.26% | 0.00% | Jun 2026 |
| UBS Group AG | 297K | 0.26% | +30.83% | Jun 2026 |
| KESTRA PRIVATE WEALTH SERVICES, LLC | 282K | 0.24% | +6.48% | Jun 2026 |
Rani Therapeutics Holdings Inc company profile
- Company name
- Rani Therapeutics Holdings Inc
- Ticker
- RANI.US
- Exchange
- USA Stocks
- Listed since
- Jul 30, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 69
- Fiscal year end
- December
- Address
- 2051 Ringwood Avenue, San Jose, CA, United States, 95131
- Phone
- 408 457 3700
- Website
- ranitherapeutics.com
About Rani Therapeutics Holdings Inc
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity; Chugai Pharmaceutical Co., Ltd. to commercialize the Chugai Product combining Chugai's Compound, which is in development for hemophilia, and the RaniPill HC oral delivery device for use in humans; and has a research and development collaboration with PegBio Co., Ltd. to expand obesity pipeline across multiple novel candidates. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Rani Therapeutics Holdings Inc management
9- Mr. Mir A. ImranExecutive Chairman · born 1956
- Mr. Talat ImranCEO & Director · born 1982
- Ms. Kate McKinley M.B.A.Chief Business Officer · born 1978
- Mr. Nicholas MaestasChief Financial Officer · born 1980
- Mr. Alireza Javadi Ph.D.Chief Technical Officer · born 1984
- Dr. Mir HashimChief Scientific Officer · born 1960
- Ms. Bella VazquezSenior Vice President of People & Administrative Services
- Mr. Jesper Hoeiland M.Sc.Head of Strategy · born 1960
- Ms. Arvinder DhallaVice President of Clinical Development